



SUPPLEMENT APPROVAL

NDA 050632/S-015

Bristol-Myers Squibb
Attention: Chand Shista
Director, Global Regulatory and Safety Science, US
P.O. Box 4000
Mail Stop D12-07
Princeton, NJ 08543-4000

Dear Mr. Shista:

Please refer to your supplemental new drug application submitted and received on December 17, 2012, under section 505(b) of the Federal Food, Drug, and Cosmetic Act for AZACTAM (aztreonam injection) in GALAXY Plastic Container (PL 2040) for Intravenous Use.

We acknowledge receipt of your amendments dated March 19 and June 14, 2013.

This “Prior Approval” labeling supplement provides for changes to the **CLINICAL PHARMACOLOGY** Section, **MICROBIOLOGY** subsection, **PRECAUTIONS** section, **Carcinogenesis, Mutagenesis, Impairment of Fertility and Pregnancy** subsections, **DOSAGE AND ADMINISTRATION** section, **Dosage in Adult Patients** and **Dosage in Pediatric Patients** subsections, and **REFERENCES** section.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Susmita Samanta, Regulatory Project Manager, at (301) 796-0803.

Sincerely,

{See appended electronic signature page}

Sumathi Nambiar, M.D., M.P.H.
Deputy Director for Safety
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure: Package Insert

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUMATHI NAMBIAR
06/17/2013